Lisaftoclax in Combination with Alrizomadlin Overcomes Venetoclax Resistance in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Preclinical Studies.

Yifan Zhai Qiuqiong Tang Douglas D Fang Jing Deng Kaixiang Zhang Qixin Wang Yan Yin Chengcheng Fu Sheng-Li Xue Na Li Feng Zhou Dajun Yang

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

Lisaftoclax in combination with alrizomadlin overcomes venetoclax resistance mediated by various mechanisms, including BCL-2 mutations. In addition, we posit further, putative molecular mechanisms. Our data rationalize clinical development of this treatment combination in patients with diseases that are insensitive or resistant to venetoclax.

Keyphrases

acute lymphoblastic leukemia
chronic lymphocytic leukemia
stem cells
big data
cell therapy
mesenchymal stem cells
combination therapy